Tetralogic Pharmaceuticals Corp Stock Performance
| TLOG Stock | USD 0.0001 0.00 0.00% |
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and TetraLogic Pharmaceuticals are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days TetraLogic Pharmaceuticals Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, TetraLogic Pharmaceuticals is not utilizing all of its potentials. The latest stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 13.1 M | |
| Total Cashflows From Investing Activities | 35.4 M |
TetraLogic |
TetraLogic Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 0.01 in TetraLogic Pharmaceuticals Corp on October 28, 2025 and sell it today you would earn a total of 0.00 from holding TetraLogic Pharmaceuticals Corp or generate 0.0% return on investment over 90 days. TetraLogic Pharmaceuticals Corp is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than TetraLogic, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
TetraLogic Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of TetraLogic Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for TetraLogic Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| TetraLogic Pharmaceuticals generated a negative expected return over the last 90 days | |
| TetraLogic Pharmaceuticals has some characteristics of a very speculative penny stock | |
| TetraLogic Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| TetraLogic Pharmaceuticals Corp currently holds 28.33 M in liabilities with Debt to Equity (D/E) ratio of 4.17, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. TetraLogic Pharmaceuticals has a current ratio of 0.47, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist TetraLogic Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, TetraLogic Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like TetraLogic Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for TetraLogic to invest in growth at high rates of return. When we think about TetraLogic Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (49.72 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| TetraLogic Pharmaceuticals Corp currently holds about 5.89 M in cash with (34.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.24, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
TetraLogic Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of TetraLogic Pink Sheet often depends not only on the future outlook of the current and potential TetraLogic Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. TetraLogic Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 23.7 M | |
| Cash And Short Term Investments | 20.4 M |
TetraLogic Pharmaceuticals Fundamentals Growth
TetraLogic Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of TetraLogic Pharmaceuticals, and TetraLogic Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on TetraLogic Pink Sheet performance.
| Return On Asset | -0.2 | |||
| Current Valuation | 458.72 K | |||
| Shares Outstanding | 24.47 M | |||
| Price To Earning | (0.03) X | |||
| Price To Book | 0.40 X | |||
| EBITDA | (43.15 M) | |||
| Cash And Equivalents | 5.89 M | |||
| Cash Per Share | 0.24 X | |||
| Total Debt | 28.33 M | |||
| Debt To Equity | 4.17 % | |||
| Book Value Per Share | (1.25) X | |||
| Cash Flow From Operations | (34.89 M) | |||
| Earnings Per Share | (1.65) X | |||
| Total Asset | 64.02 M | |||
| Retained Earnings | (175.56 M) | |||
| Current Asset | 21.97 M | |||
| Current Liabilities | 3.66 M | |||
About TetraLogic Pharmaceuticals Performance
By analyzing TetraLogic Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into TetraLogic Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if TetraLogic Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if TetraLogic Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. Tetralogic Pharmaceu operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 29 people.Things to note about TetraLogic Pharmaceuticals performance evaluation
Checking the ongoing alerts about TetraLogic Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for TetraLogic Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| TetraLogic Pharmaceuticals generated a negative expected return over the last 90 days | |
| TetraLogic Pharmaceuticals has some characteristics of a very speculative penny stock | |
| TetraLogic Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| TetraLogic Pharmaceuticals Corp currently holds 28.33 M in liabilities with Debt to Equity (D/E) ratio of 4.17, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. TetraLogic Pharmaceuticals has a current ratio of 0.47, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist TetraLogic Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, TetraLogic Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like TetraLogic Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for TetraLogic to invest in growth at high rates of return. When we think about TetraLogic Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (49.72 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| TetraLogic Pharmaceuticals Corp currently holds about 5.89 M in cash with (34.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.24, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing TetraLogic Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether TetraLogic Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining TetraLogic Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating TetraLogic Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of TetraLogic Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of TetraLogic Pharmaceuticals' pink sheet. These opinions can provide insight into TetraLogic Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for TetraLogic Pink Sheet analysis
When running TetraLogic Pharmaceuticals' price analysis, check to measure TetraLogic Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TetraLogic Pharmaceuticals is operating at the current time. Most of TetraLogic Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of TetraLogic Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TetraLogic Pharmaceuticals' price. Additionally, you may evaluate how the addition of TetraLogic Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |